CDK4 and cancer: However, pre-clinical data on multiple cancer models indicate that the predominantly reversible cytostatic responses to palbociclib or other CDK4/6 inhibitors can be converted into irreversible cell cycle arrest and senescence or apoptosis through combinations with other targeted drugs (23, 25, 58, 59) or chemotherapy (60).